首页> 外文OA文献 >PCV95 A Conservative Approach To Assess Warfarin Time-In-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients In An Integrated Healthcare Delivery System Setting In The U.S

【2h】

PCV95 A Conservative Approach To Assess Warfarin Time-In-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients In An Integrated Healthcare Delivery System Setting In The U.S

机译：PCV95在美国综合医疗服务提供系统中评估非瓣膜性房颤患者华法林治疗时程的保守方法

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Deitelzweig S.; Evans M.; Hillson E.; Trocio J.; Bruno A.; Tan W.; Lingohr-Smith M.; Lin J.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation [J] . Deitelzweig Steve, Evans Michael, Hillson Eric, Current medical research and opinion . 2016,第1期

机译：华法林在治疗范围内的时间及其对非瓣膜性房颤患者的医疗资源利用和成本的影响
2. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting [J] . Mahajan Dheeraj, Wu Bingcao, Song Ji, Drugs and aging . 2020,第4期

机译：在熟练护理设施中的非衰弱性心房颤动的罗昔班和华法林的医疗资源利用和成本的比较
3. COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION IN THE GUANGDONG HEALTHCARE SETTING IN CHINA [J] . Zhou J., Huang B. Y., Yang M. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：利伐沙班与华法林预防中国广东省非瓣膜性心房纤颤卒中的成本效益
4. Dabigatran versus warfarin for the prevention of stroke in patients with chronic nonvalvular atrial fibrillation. [D] . Qiu, Fen. 2011

机译：达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
5. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach [O] . Xiaoyan Li, Allison Keshishian, Melissa Hamilton, -1

机译：与华法林相比阿哌沙班5和2.5 mg每天两次与非华法林在非瓣膜性房颤患者中预防卒中：使用倾向评分匹配方法评估比较有效性和安全性
6. DOES WARFARIN TIME-IN-THERAPEUTIC RANGE AFFECT HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN THE U.S.? [O] . Deitelzweig Steven, Evans Michael, Hillson Eric, 2015

机译：在非瓣膜性心房颤动患者中，Warfarin的治疗时间范围是否会影响医疗资源的利用和成本？

PCV95 A Conservative Approach To Assess Warfarin Time-In-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients In An Integrated Healthcare Delivery System Setting In The U.S

著录项

相似文献

相关主题

期刊订阅